DK2575596T3 - Fremgangsmåde til bestemmelse af amyloid-beta-omsætning i blod. - Google Patents
Fremgangsmåde til bestemmelse af amyloid-beta-omsætning i blod. Download PDFInfo
- Publication number
- DK2575596T3 DK2575596T3 DK11787251.5T DK11787251T DK2575596T3 DK 2575596 T3 DK2575596 T3 DK 2575596T3 DK 11787251 T DK11787251 T DK 11787251T DK 2575596 T3 DK2575596 T3 DK 2575596T3
- Authority
- DK
- Denmark
- Prior art keywords
- labeled
- hours
- label
- blood
- amino acid
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4709—Amyloid plaque core protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- General Health & Medical Sciences (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Optics & Photonics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Claims (11)
1
1. In vitro-fremgangsmåde til måling af in vivo-omsætningen af Αβ i blodet fra et subjekt, hvor fremgangsmåden omfatter: (a) at bestemme mængden af mærket Αβ ved massespektroskopi eller mængden af såvel mærket Αβ og ikke-mærket Αβ i en blodprøve opnået fra subjektet; og (b) at beregne omsætningen af Αβ ved anvendelse af mængden af mærket Αβ eller mængden af såvel mærket Αβ og ikke-mærket Αβ, bestemt i trin (a), hvor (i) Αβ-omsætning beregnes fra mængden af mærket Αβ eller mængden af mærket Αβ og ikke-nærket Αβ, i en prøve opnået mellem 15 minutter og 4 timer efter oral eller intravenøs indgivelse er påbegyndt, af mindst én aminosyre, der er mærket med en stabil ikke-radioaktiv isotop til subjektet; eller (ii) Αβ-omsætning bestemmes fra maksimumsværdien af fremstillingen af mærket Αβ, der sker mellem omkring 1 og 5 timer efter oral bolusindgivelse påbegyndes af mindst én aminosyre, der er mærket med en stabil ikke-radioaktiv isotop til subjektet eller mellem omkring 5 og 10 timer efter intravenøs indgivelse påbegyndes ved en 9 timers infusion af mindst én aminosyre, der er mærket med en stabil ikke-radioaktiv isotop til subjektet.
2. Fremgangsmåde ifølge krav 1, hvor den orale bolusindgivelse af del (b)(ii) substitueres med en IV-bolus.
3. Fremgangsmåde ifølge krav 1, hvor den mærkede aminosyre indgives oralt.
4. Fremgangsmåde ifølge krav 3, hvor mellem omkring 0,05g og omkring 8g af aminosyre, der er mærket med en stabil ikke-radioaktiv isotop indgives.
5. Fremgangsmåde ifølge krav 1, hvor den mærkede aminosyre indgives intravenøst.
6. Fremgangsmåde ifølge krav 5, hvor den mærkede aminosyre indgives som en infusion ved mellem omkring 0,01mg/kg/hour og omkring 3 mg/kg/hour.
7. Fremgangsmåde ifølge krav 1, hvor trin (a) yderligere omfatter indledningsvist at isolere Αβ fra blodprøven.
8. Fremgangsmåde ifølge krav 1, hvor den mindst éne blodprøve tages efter omkring 30 minutter efter indgivelse af mindst én mærket aminosyre til subjektet.
9. Fremgangsmåde ifølge krav 1, hvor mængden af mærket Αβ eller ikke-mærket Αβ er valgt fra gruppen bestående af samlet Αβ, Αβ38, Αβ40, og Αβ42.
10. Fremgangsmåde ifølge krav 1, yderligere omfattende at bestemme den absolutte kvantificering af Αβ i prøven.
11. Fremgangsmåde ifølge krav 10, hvor omsætningen af Αβ bestemmes ved anvendelse af produktet af den procentvise mærkede Αβ og den absolutte kvantificering af Αβ.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US34755410P | 2010-05-24 | 2010-05-24 | |
| PCT/US2011/037754 WO2011149947A2 (en) | 2010-05-24 | 2011-05-24 | Methods of determining amyloid beta turnover in blood |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2575596T3 true DK2575596T3 (da) | 2016-08-01 |
Family
ID=45004715
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK11787251.5T DK2575596T3 (da) | 2010-05-24 | 2011-05-24 | Fremgangsmåde til bestemmelse af amyloid-beta-omsætning i blod. |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US20130115716A1 (da) |
| EP (2) | EP2575596B1 (da) |
| JP (2) | JP5886837B2 (da) |
| KR (1) | KR20130116792A (da) |
| AU (1) | AU2011258462B2 (da) |
| BR (1) | BR112012029985A2 (da) |
| CA (1) | CA2800680C (da) |
| DK (1) | DK2575596T3 (da) |
| ES (1) | ES2583033T3 (da) |
| WO (1) | WO2011149947A2 (da) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009062152A1 (en) * | 2007-11-09 | 2009-05-14 | Washington University In St. Louis | Methods for measuring the metabolism of cns derived biomolecules in vivo |
| AU2012359020B2 (en) * | 2011-12-19 | 2017-04-13 | The Washington University | Methods for diagnosing Alzheimer's disease |
| WO2014160647A1 (en) * | 2013-03-24 | 2014-10-02 | The Washington University | Method for amyloid beta sample processing |
| IL245703B (en) * | 2013-11-20 | 2022-07-01 | Univ Iowa Res Found | Methods and preparations for the treatment of amyloid deposits |
| EP3200832B1 (en) | 2014-09-30 | 2020-07-29 | Washington University | Tau kinetic measurements |
| JP2018528404A (ja) * | 2015-06-30 | 2018-09-27 | ヘルス リサーチ インコーポレイテッドＨｅａｌｔｈ Ｒｅｓｅａｒｃｈ， Ｉｎｃ． | タンパク質分解経路の特定に基づくアルツハイマー病の診断テスト |
| WO2018204406A1 (en) | 2017-05-01 | 2018-11-08 | Washington University | BLOOD-BASED METHODS FOR DETERMINING Aβ AMYLOIDOSIS |
| US11085935B2 (en) | 2018-05-03 | 2021-08-10 | Washington University | Methods of treating based on site-specific tau phosphorylation |
| WO2021009074A1 (en) | 2019-07-12 | 2021-01-21 | Adx Neurosciences Nv | Novel markers as early predictors of alzheimer's pathology |
| JPWO2022176612A1 (da) * | 2021-02-22 | 2022-08-25 | ||
| WO2024133743A1 (en) * | 2022-12-21 | 2024-06-27 | EM Scientific Limited | Method for diagnosing and/or classifying the severity of a neurodegenerative disease |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003068919A2 (en) * | 2002-02-12 | 2003-08-21 | The Regents Of The University Of California | Non-invasive method for measuring rates of biosynthesis of biological molecules by label incorporation |
| US20040096907A1 (en) * | 2002-11-06 | 2004-05-20 | Bernd Bohrmann | Quantification of beta amyloid |
| JP2008509421A (ja) * | 2004-08-07 | 2008-03-27 | キナメッド・インコーポレイテッド | インビボにおける生体分子の自己集合性システムのダイナミクスの測定方法および治療剤の発見または評価のための使用 |
| WO2006107814A2 (en) * | 2005-04-06 | 2006-10-12 | Washington University In St. Louis | Methods for measuring the metabolism of neurally derived biomolecules in vivo |
| CA2745839C (en) * | 2008-12-05 | 2017-09-19 | C2N Diagnostics | Methods for measuring concentrations of biomolecules |
-
2011
- 2011-05-24 US US13/699,497 patent/US20130115716A1/en not_active Abandoned
- 2011-05-24 AU AU2011258462A patent/AU2011258462B2/en active Active
- 2011-05-24 WO PCT/US2011/037754 patent/WO2011149947A2/en active Application Filing
- 2011-05-24 ES ES11787251.5T patent/ES2583033T3/es active Active
- 2011-05-24 BR BR112012029985A patent/BR112012029985A2/pt not_active IP Right Cessation
- 2011-05-24 EP EP11787251.5A patent/EP2575596B1/en active Active
- 2011-05-24 DK DK11787251.5T patent/DK2575596T3/da active
- 2011-05-24 JP JP2013512165A patent/JP5886837B2/ja active Active
- 2011-05-24 EP EP16158001.4A patent/EP3066979B1/en active Active
- 2011-05-24 CA CA2800680A patent/CA2800680C/en active Active
- 2011-05-24 KR KR1020127033176A patent/KR20130116792A/ko not_active Application Discontinuation
-
2016
- 2016-02-10 JP JP2016023884A patent/JP6293802B2/ja active Active
-
2017
- 2017-02-01 US US15/422,165 patent/US20170146557A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU2011258462A1 (en) | 2012-12-13 |
| JP6293802B2 (ja) | 2018-03-14 |
| EP2575596A2 (en) | 2013-04-10 |
| KR20130116792A (ko) | 2013-10-24 |
| JP2016153788A (ja) | 2016-08-25 |
| BR112012029985A2 (pt) | 2017-02-21 |
| CA2800680A1 (en) | 2011-12-01 |
| EP2575596A4 (en) | 2013-12-04 |
| ES2583033T3 (es) | 2016-09-16 |
| EP3066979B1 (en) | 2017-11-01 |
| EP3066979A1 (en) | 2016-09-14 |
| JP2013532277A (ja) | 2013-08-15 |
| EP2575596B1 (en) | 2016-04-20 |
| AU2011258462B2 (en) | 2015-01-15 |
| WO2011149947A3 (en) | 2012-01-26 |
| CA2800680C (en) | 2018-08-28 |
| WO2011149947A2 (en) | 2011-12-01 |
| JP5886837B2 (ja) | 2016-03-16 |
| US20170146557A1 (en) | 2017-05-25 |
| US20130115716A1 (en) | 2013-05-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2575596T3 (da) | Fremgangsmåde til bestemmelse af amyloid-beta-omsætning i blod. | |
| AU2012359020B2 (en) | Methods for diagnosing Alzheimer's disease | |
| US20210096139A1 (en) | Tau kinetic measurements | |
| EP3028049A2 (en) | Diagnostic tools for alzheimer's disease | |
| Robinson et al. | Release of skeletal muscle peptide fragments identifies individual proteins degraded during insulin deprivation in type 1 diabetic humans and mice | |
| Janzen et al. | UPLC–MS/MS analysis of C5-acylcarnitines in dried blood spots | |
| AU2017200029B2 (en) | Methods of determining amyloid beta turnover in blood | |
| CN113252806B (zh) | S-腺苷同型半胱氨酸在制备用于诊断或治疗川崎病的产品中的用途 | |
| AU2014265047A1 (en) | Simultaneous measurement of the in vivo metabolism of isoforms of a biomolecule | |
| Nair | Release of skeletal muscle peptide fragments identifies individual proteins 1 degraded during insulin deprivation in Type-I Diabetic humans and mice 2 3 Matthew M. Robinson1, Surendra Dasari2, Helen Karakelides1, H. Robert Bergen 3rd 3, 4 and K. Sreekumaran Nair1 5 | |
| Khambule | ASSOCIATION OF BRANCHED CHAIN AMINO ACIDS AND AROMATIC AMINO ACIDS WITH CARDIO-METABOLIC RISK FACTORS |